All In Biotech

Free tool

FAERS Monitor: Dojolvi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213687 or its brand name (Dojolvi, Triheptanoin). Reports on generic versions are filed under their own applications.

Reports

554

Serious

350

63% of reports

Hospitalization

268

Death reported

69

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • vomiting88
  • diarrhoea77
  • rhabdomyolysis56
  • off label use53
  • abdominal pain upper44
  • abdominal discomfort36
  • blood creatine phosphokinase increased35
  • death33
  • nausea29
  • illness25
  • gastrointestinal disorder24
  • hospitalisation24
  • abdominal pain21
  • metabolic disorder20
  • product dose omission issue17

Reports by year received

View as table
YearReports
202027
202190
2022117
2023114
202499
202567
202640

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,605 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
metabolic disorderSignal20131.285.32,448
rhabdomyolysisSignal5651.139.82,700
blood creatine phosphokinase increasedSignal3546.233.51,504
gastrointestinal disorderSignal2410.26.9190
illnessSignal259.26.3176
abdominal discomfortSignal368.15.9220
abdominal pain upperSignal448.16.1270
vomitingSignal887.15.9466
hospitalisationSignal245.94.094
diarrhoeaSignal774.53.7215
abdominal painSignal213.42.334
off label useSignal532.31.839
product dose omission issueSignal172.21.410
death331.51.04
nausea291.41.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.